End-of-day quote
Shenzhen S.E.
06:00:00 2024-05-14 pm EDT
5-day change
1st Jan Change
13.85
CNY
-0.93%
-2.46%
-6.29%
Yifan Pharmaceutical Co., Ltd.'s Equity Buyback announced on August 31, 2023, has closed with 2,412,900 shares, representing 0.2% for CNY 38 million.
The company closed its plan on December 19, 2023.
Yifan Pharmaceutical Unit Gets Authorization to Sell Circulation Supplement in Singapore
May. 14
MT
Yifan Unit's Allergy Drug Passes China Regulatory Test, Stock Price Jumps
Apr. 25
MT
Yifan Pharmaceutical's Unit Gets Nod to Register Nimodipine Injection
Apr. 25
MT
Three Drugs of Yifan Pharmaceutical's Unit Placed in China's Centralized Procurement
Apr. 25
MT
Yifan Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
Apr. 23
CI
Yifan Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
Apr. 19
CI
Yifan Pharmaceutical Gets EU Nod to Sell Ryzneuta Drug
Mar. 26
MT
Tranche Update on Yifan Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on August 31, 2023.
Dec. 19
CI
Yifan Pharmaceutical Co., Ltd.'s Equity Buyback announced on August 31, 2023, has closed with 2,412,900 shares, representing 0.2% for CNY 38 million.
Dec. 18
CI
Yifan Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
23-10-30
CI
Tranche Update on Yifan Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on August 31, 2023.
23-10-09
CI
Yifan Pharmaceutical Co., Ltd. announces an Equity Buyback for CNY 50 million worth of its shares.
23-08-30
CI
Yifan Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
23-08-29
CI
Yifan Pharmaceutical Co., Ltd. authorizes a Buyback Plan.
23-08-28
CI
Yifan Pharma CFO Resigns; Successor Named
23-07-10
MT
Yifan Pharma Registers Leukemia Drug in China
23-06-30
MT
Yifan Pharmaceutical Registers Coronary Syndrome Treatment
23-06-21
MT
Yifan Pharmaceutical Unit Registers Cancer Treatment in China
23-05-10
MT
Yifan Pharmaceutical Registers Dopamine Hydrochloride
23-05-09
MT
Yifan Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
23-04-28
CI
Yifan Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
23-04-14
CI
Yifan Pharma Gets Nod to Register Another Hypotension Drug
23-03-27
MT
Yifan Pharmaceutical Registers Blood Pressure Control Drug
23-03-23
MT
Yifan Pharma Registers Seizure Drug in China
23-03-13
MT
Yifan Pharmaceutical Gets Registration Certificate for Lacosamide Tablets
23-02-27
MT
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
YIFAN XINFU PHARMACEUTICAL CO.,LTD, is a China-based company primarily engaged in production and sale of polymer materials. The Company operates in three segments, including Pharmaceuticals, Pharmaceutical Raw Material and Intermediates, as well as Polymer Materials. The Company's main products include D-calcium pantothenate, D- panthenol, poly butylenes succinate and others. The Company distributes its products in domestic and overseas markets.
More about the company
Last Close Price
13.85
CNY
Average target price
19
CNY
Spread / Average Target
+37.18%
Consensus
1st Jan change
Capi.
-6.29% 2.33B +20.86% 43.92B +24.56% 23.09B +19.55% 15.35B +13.17% 13.61B +46.13% 12.02B -10.14% 7B -0.05% 6.79B -8.87% 5.73B +13.07% 5.6B
Generic Pharmaceuticals
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
marketscreener.com**derivatives**en**/dynamic-chart/**Premium**Expert**Access**Annual**Monthly**
-40% Limited Time Offer : Our subscriptions help you unlock hidden opportunities.**#000000**/services/solutions/**#fff826**#ff3000**#ffffff**
BENEFIT NOW **0**linear-gradient(180deg, rgba(42,73,76,1) 0%, rgba(28,30,51,1) 53%);**linear-gradient(180deg, rgba(255, 248, 38,1) 0%, rgba(247, 239,1) 53%);**date_fin_hors_prolongation**49**on all our subscriptions**